undamentalytics Newsletter
Sign in

Biorestorative Therapies, Inc. revenue

Biorestorative Therapies, Inc.'s revenue was $359,700 in fiscal 2025, down 10.3% on the year before. Since fiscal 2012 ($15,589) it has grown at a compound 27.3% a year. Over the last twelve months it was $357,870.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMMar 2026
Revenue016241662936811111307746120146401360358
Growth on the year before——−89.2%+>999%+51.2%−94.2%+122.8%+37.0%+17.1%−40.8%−40.3%+160.4%+21.7%+175.0%−10.3%—
Gross profit01412023673681—————146373336330

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $300,000 83.4% 0.0%
Royalty $59,700 16.6% ▼ 40.9%

From Biorestorative Therapies, Inc.'s 10-K filed March 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Biorestorative Therapies, Inc. $357,870 -8.5% 38.4%
Cervomed Inc. $331,295 -95.7% -52.7%
Cardiff Oncology, Inc. $508,000 -7.0% 7.2%
Clene Inc. $197,000 -31.1% -36.9%
Celldex Therapeutics, Inc. $158,000 -97.3% -63.5%
Medicinova Inc $920,481 875.7% —

Compare with peers

Head to head: BRTX vs CRVOBRTX vs CRDFBRTX vs CLNN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Biorestorative Therapies, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Biorestorative Therapies, Inc.